Business Description
Tenax Therapeutics Inc
NAICS : 541714
SIC : 8731
ISIN : US88032L2097
Description
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 352.37 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 73.3 | |||||
| 3-Year EPS without NRI Growth Rate | 72.7 | |||||
| 3-Year FCF Growth Rate | 75.1 | |||||
| 3-Year Book Growth Rate | -64.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 57.42 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 38.95 | |||||
| Quick Ratio | 38.95 | |||||
| Cash Ratio | 38.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -235.6 | |||||
| Shareholder Yield % | -525.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -52.79 | |||||
| ROA % | -49.05 | |||||
| ROIC % | -1977.6 | |||||
| ROC (Joel Greenblatt) % | -5561.48 | |||||
| ROCE % | -52.69 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.19 | |||||
| Price-to-Tangible-Book | 0.19 | |||||
| EV-to-EBIT | -0.69 | |||||
| EV-to-EBITDA | -0.69 | |||||
| EV-to-Forward-Revenue | 0.06 | |||||
| EV-to-FCF | -0.8 | |||||
| Price-to-Net-Current-Asset-Value | 0.19 | |||||
| Price-to-Net-Cash | 0.2 | |||||
| Earnings Yield (Greenblatt) % | -144.93 | |||||
| FCF Yield % | -66.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tenax Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -13.727 | ||
| Beta | 0 | ||
| Volatility % | 69.95 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 161.6 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 161.6 - 161.6 | ||
| Shares Outstanding (Mil) | 1.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tenax Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tenax Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tenax Therapeutics Inc Frequently Asked Questions
What is Tenax Therapeutics Inc(FRA:YBO0)'s stock price today?
The current price of FRA:YBO0 is €161.60. The 52 week high of FRA:YBO0 is €161.60 and 52 week low is €161.60.
When is next earnings date of Tenax Therapeutics Inc(FRA:YBO0)?
The next earnings date of Tenax Therapeutics Inc(FRA:YBO0) is 2025-02-13 Est..
Does Tenax Therapeutics Inc(FRA:YBO0) pay dividends? If so, how much?
Tenax Therapeutics Inc(FRA:YBO0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers